Navigation Links
Yew Bio-Pharm Group Announces Second-Quarter 2013 Results
Date:8/13/2013

HARBIN, China, Aug. 13, 2013 /PRNewswire/ -- Yew Bio-Pharm Group, Inc. ("Yew Bio" or the "Company") (OTCBB: YEWB), a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine and products made from yew timber in China, today announced financial results for the second quarter ended June 30, 2013.

Second-Quarter Financial and Operating Highlights:

  • Total revenues were $2.1 million, a 10.5% increase from $1.9 million in the year-ago quarter
  • Revenue from the sale of yew trees was $0.8 million, an increase of 18.3% from the year-ago quarter
  • Gross profit was $1.6 million, in line with the year-ago quarter.  The gross margin was 76.0%, as compared with 84.4% in the year-ago quarter
  • Operating profit was $1.3 million, as compared to $1.5 million in the year-ago quarter
  • Net income was $1.3 million, or $0.03 per diluted share, as compared to $1.5 million, or $0.03 per diluted share, in the year-ago quarter
  • "We are pleased to report a solid increase in revenues driven by sales growth in all our product categories, which offset higher expenses in the second quarter of 2013," commented Mr. Zhiguo Wang, Chairman and Chief Executive Officer of Yew Bio. "We are building upon the recent approval by the Financial Industry Regulatory Authority (FINRA) for our stock to trade on the OTC Bulletin Board and the eligibility of our shares by the Depository Trust Corporation (DTC) for electronic trading by investors, and we look forward to sharing further details of our business with our shareholders in the future."Second-Quarter 2013 Financial ResultsThree Months Ended June 30,Six Months Ended June 30,2013201220132012Revenues:TCM Raw Materials$1,270,330$1,225,360$2,166,491$1,966,643Yew Trees796,653673,5651,653,6071,457,088Handicrafts39,3836,49685,20836,035Total Revenues$2,106,366$1,905,421$3,905,306$3,459,766Total revenues in the second quarter of 2013 were $2.1 million, an increase of 10.5% from $1.9 million in the year-ago quarter. The revenue increase was primarily due to an 18.3% increase in revenue from sales of yew trees, and revenues increased year-over-year in all product categories.  Sales of TCM raw materials amounted to 49.8% of total revenues, sales of yew trees amounted to 47.6% of total revenues, and sales of handicrafts made up the remaining 2.6%.

    Total cost of revenues was $0.5 million, a 69.8% increase from $0.3 million in the year-ago quarter.  Gross profit was $1.6 million, roughly in line with the year-ago quarter.  The gross margin was 76.0% in the quarter, as compared to 84.4% in the year-ago quarter. Gross margins declined year-over-year due to higher margins from the sale of yew trees being more than offset by lower margins from the sale of TCM raw materials and handicrafts.

    Operating expenses were $0.3 million in the quarter, as compared to $0.2 million in the year-ago quarter.  Operating expenses increased year-over-year primarily due to higher general and administrative expense.  Operating income and net income was $1.3 million, as compared to operating income of $1.5 million in the year-ago quarter.

    Net income in the second quarter of 2013 was $1.3 million, as compared to $1.5 million in the year-ago quarter.  Earnings per diluted share were $0.03, in line with the same period last year.

    Six Months 2013 Financial ResultsTotal revenues for the six months ended June 30, 2013 were $3.9 million, a 12.9% increase from $3.5 million in the same period last year.  The revenue increase was primarily due to a 13.5% increase in revenue from sales of yew trees, and revenues increased period-over-period in all product categories.  Sales of TCM raw materials amounted to 55.5% of total revenues, sales of yew trees amounted to 42.3% of total revenues, and sales of handicrafts made up the remaining 2.2%.

    Total cost of revenues increased 27.8% to $1.1 million from $0.6 million in the same period last year.  Gross profit was $2.8 million, as compared to $2.9 million in the same period last year.  The gross margin was 72.2% in the six months ended June 30, 2013, as compared to 82.5% in the year-ago period. Gross margins declined year over year due to lower margins in all product categories.

    Operating expenses were $0.6 million in the six months ended June 30, 2013, as compared to $0.4 million in the same period last year.  Operating expenses increased year-over-year primarily due to higher general and administrative expense.  Operating income and net income was $2.3 million in the six month period ended June 30, 2013, as compared to operating income of $2.5 million in the same period last year.

    Net income in the first half of 2013 was $2.3 million, as compared to $2.5 million in the year-ago quarter.  Earnings per diluted share were $0.05 in the six-month period ended June 30, 2013, in line with the same period last year.

    ABOUT YEW BIO-PHARM GROUP, INCYew Bio-Pharm Group, Inc., through its operating entity, Harbin Yew Science and Technology Development Co., Ltd. (HDS), is a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine (TCM) and products made from yew timber in China. Raw material from the species of yew tree that the Company grows contains taxol, and TCM containing yew raw materials has been approved as a traditional Chinese medicine in China for secondary treatment of certain cancers.  The Company uses a patented, accelerated growth technology to speed the growth and maturity and commercialization of yew trees and believes that it is one of the few companies possessing a permit to sell them.

    SAFE HARBORThis press release forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act.  These forward-looking statements involve a number of risks and uncertainties that could cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements.  A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: our ability to collect from our largest customers; our dependence on a small number of customers for raw materials, including a related party; our ability to continue to purchase raw materials at relatively stable prices; our dependence on a small number of customers for our yew trees for reforestation; our ability to market successfully raw materials used in the manufacture of traditional Chinese medicines; and our ability to receive continued preferential tax treatment for the sale of yew trees and potted yew trees.  From time to time, these risks, uncertainties and other factors are discussed in the Company's filings with the U.S. Securities and Exchange Commission, including its most recent annual report on Form 10-K.  Yew Bio does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise, except as required under applicable law.

    - financial tables follow-YEW BIO-PHARM GROUP, INC. AND SUBSIDIARIESCONSOLIDATED BALANCE SHEETSJune 30, 2013December 31,(Unaudited)2012ASSETSCURRENT ASSETS:Cash

    $30,021$386,821Accounts receivable

    1,767,073722,598Accounts receivable - related party

    1,486,700284,986Inventories

    1,247,219991,234Prepaid expenses and other assets

    24,465150Prepaid expenses - related parties

    47,55660,245Total Current Assets

    4,603,0342,446,034LONG-TERM ASSETS:Inventories, net of current portion

    9,755,4249,382,164Property and equipment, net

    801,397885,969Land use rights and yew forest assets, net

    15,736,29015,328,318Total Long-term Assets

    26,293,11125,596,451Total Assets

    30,896,14528,042,485LIABILITIES AND SHAREHOLDERS' EQUITYCURRENT LIABILITIES:Accounts payable

    3,996990Accrued expenses and other payables

    187,423199,098Taxes payable 

    2,9975,722Due to related parties

    50,38747,876Total Current Liabilities

    244,803253,686Total Liabilities

    244,803253,686COMMITMENTS AND CONTINGENCIESSHAREHOLDERS' EQUITY:
    Preferred stock ($0.001 par value; 10,000,000 shares authorized, no shares
    issued and outstanding at June 30, 2013 and December 31, 2012, respectively)

    ––Common stock ($0.001 par value;  140,000,000 shares authorized; 50,000,000 issued and outstanding at June 30, 2013 and December 31, 2012, respectively)

    50,00050,000Additional paid-in capital

    10,396,37710,396,377Retained earnings

    15,199,56813,182,032Statutory reserves

    2,426,9782,179,494Accumulated other comprehensive income - foreign currency translationadjustment

    2,578,4191,980,896Total Shareholders' Equity

    30,651,34227,788,799Total Liabilities and Shareholders' Equity

    30,896,14528,042,485 YEW BIO-PHARM GROUP, INC. AND SUBSIDIARIES  CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME  (UNAUDITED)  For the Three MonthsEnded June 30,  For the Six Months Ended June 30, 2013201220132012 REVENUES: Revenues 

    $1,143,880$1,905,421$2,584,871$3,300,074Revenues - related party 

    962,486–1,320,435159,692Total Revenues 

    2,106,3661,905,4213,905,3063,459,766 COST OF REVENUES: Cost of revenues 

    206,310297,744701,969580,548Cost of revenues - related party 

    299,212–382,22225,224Total Cost of Revenues 

    505,522297,7441,084,191605,772 GROSS PROFIT 

    1,600,8441,607,6772,821,1152,853,994 OPERATING EXPENSES: Selling 

    6,0795,35011,69311,237General and administrative 

    271,908150,062543,869363,773Total Operating Expenses 

    277,987155,412555,562375,010 INCOME FROM OPERATIONS 

    1,322,8571,452,2652,265,5532,478,984 OTHER INCOME (EXPENSES): Interest income 

    421,509841,588Other income (expense) 

    (200)(361)(617)(361)Total Other Income (Expenses) 

    (158)1,148(533)1,227 NET INCOME 

    1,322,6991,453,4132,265,0202,480,211 COMPREHENSIVE INCOME: NET INCOME 

    1,322,6991,453,4132,265,0202,480,211OTHER COMPREHENSIVE INCOME: Foreign currency translation adjustment 

    442,87121,762597,523167,667COMPREHENSIVE INCOME 

    1,765,5701,475,1752,862,5432,647,878 NET INCOME PER COMMON SHARE: Basic 

    $0.03$0.03$0.05$0.05Diluted$0.03$0.03$0.05$0.05 WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: Basic 

    50,000,00050,000,00050,000,00045,563,187Diluted50,000,00050,000,00050,000,00050,000,000 YEW BIO-PHARM GROUP, INC. AND SUBSIDIARIES  CONSOLIDATED STATEMENTS OF CASH FLOWS  (UNAUDITED)  For the Six Months Ended June 30, 20132012 CASH FLOWS FROM OPERATING ACTIVITIES:  Net income 

    $ 2,265,020$ 2,480,211 Adjustments to reconcile net income to net cash provided by operating

     activities: Depreciation 

    102,954103,200Amortization of land use rights and yew forest assets178,817172,171Loss on disposal of fixed assets420– Changes in operating assets and liabilities: Accounts receivable 

    (1,019,696)(316,181)Accounts receivable - related party 

    (1,184,390)–Prepaid expenses and other assets 

    (24,082)(1,739)Prepaid expenses - related parties 

    13,801(70,625)Inventories 

    (186,105)(40,286)Accounts payable 

    2,957(1,306,617)Accrued expenses and other payables 

    (14,358)(40,191)Due to related parties 

    2,44822,473Taxes payable 

    (2,824)655Advances from customers 

    –232,077 NET CASH PROVIDED BY OPERATING ACTIVITIES 

    134,9621,235,148 CASH FLOWS FROM INVESTING ACTIVITIES:  Purchase of property and equipment 

    (3,084)(46,305) Payments for yew forest assets 

    (493,878)– Deposit on land use right 

    –(995,969) NET CASH USED IN INVESTING ACTIVITIES 

    (496,962)(1,042,274) CASH FLOWS FROM FINANCING ACTIVITIES:  Repayments for related parties advances–(236,595) NET CASH USED IN FINANCING ACTIVITIES 

    –(236,595) EFFECT OF EXCHANGE RATE ON CASH 

    5,2005,258 NET DECREASE IN CASH 

    (356,800)(38,463) CASH - beginning of period 

    386,821732,371 CASH - end of period 

    30,021693,908 Company Contacts:Yew Bio-Pharm Group, Inc.

    Ms. Sha Jin

    Tel: (702) 487-4683

    E-mail: hdsusasj@gmail.comInvestor Relations Contacts:

    CCG Investor Relations

    Mr. John Harmon, CFA, Sr. Account Manager

    Tel: +86 (10) 8573 1014 (Beijing)

    E-mail: john.harmon@ccgir.com
    '/>"/>

    SOURCE Yew Bio-Pharm Group, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Bio-pharma Internal Communications Groups Evolving for Structure Optimization
    2. Educating, Informing, and Successfully Preparing the Marketplace for New Bio-Pharma Products
    3. Simcere Pharmaceutical Group Reports Preliminary Unaudited Second Quarter 2013 Results
    4. AtlantiCare Heart Heroes group donates Cardiac Science AED to Atlantic City public access defibrillation program
    5. Hoosier Oncology Group Selects OnCore to Support Clinical Trials Network
    6. Linde Distributor Association, at twenty, is a leading buying group in the U.S.
    7. CAO Group Continues to Lead Innovation With launch of New, High Technology Turbo Forensic Light System
    8. Orange County Physician Owned Medical Group Opens Pioneering Medical Facility
    9. Simcere Pharmaceutical Group to Announce Second Quarter 2013 Financial Results on Tuesday, August 13, 2013
    10. Safety Net Clinic and Hospital User Group Forms to Collaborate on 340B Drug Program Best Practices and Transparency Initiatives
    11. Comco Plastics Inc. Announces Its Expansion & Separation From The NYTEF Group.
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/26/2016)... 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) ... measures required to build a strong and stable market ... listed on the OTC Markets-pink current trading platform. ... "We are seeing an anomaly in market trading activities ... by the Company, but shareholders and market players as ...
    (Date:6/24/2016)... N.C. , June 24, 2016  Consumers ... decisions and regulators/payers have placed more emphasis on ... environment, patient support programs in the pharmaceutical industry ... patients, medications. Consequently, pharmaceutical companies are focusing on ... they are providing products and services that improve ...
    (Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
    Breaking Medicine Technology:
    (Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
    (Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
    (Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
    (Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
    (Date:6/24/2016)... ... ... makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum ... by 2020 and then adjusting it yearly to increase at the same rate as the ... wage floor does not erode again, and make future increases more predictable. , The company ...
    Breaking Medicine News(10 mins):